Brief: Citius Pharmaceuticals And Citius Oncology Announce Promising Preliminary Results Of An Investigator-Initiated Phase I Clinical Trial Of Pembrolizumab (KEYTRUDA) And LYMPHIR In Cancer Patients With Recurrent Solid Tumors
11/11/2024 13:49
Nov 11 (Reuters) - Citius Pharmaceuticals Inc CTXR.O :
* CITIUS PHARMACEUTICALS, INC. AND CITIUS ONCOLOGY, INC.
ANNOUNCE
PROMISING PRELIMINARY RESULTS OF AN INVESTIGATOR-INITIATED PHASE
I CLINICAL TRIAL OF PEMBROLIZUMAB (KEYTRUDA®) AND LYMPHIR™ IN
CANCER PATIENTS WITH RECURRENT SOLID TUMORS
* CITIUS PHARMACEUTICALS: CHEMOTHERAPY-FREE IMMUNOMODULATORY
REGIMEN WELL-TOLERATED WITH NO SERIOUS IMMUNE-RELATED ADVERSE
EVENTS
Source text: ID:nPn93R1Bva
Further company coverage: CTXR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Citius Pharmaceuticals
See all newsCitius Pharmaceuticals Q2 revenue rises on LYMPHIR launch
Citius Pharmaceuticals reports first revenue of $3.9 mln
Brief: Citius Oncology Expands International Distribution Of Lymphir™ To European Union Through Exclusive Agreement With Uniphar
Brief: Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results And Provides Business Update
Brief: Citius Oncology Announces $18 Million Concurrent Registered Direct Offering And Private Placement Priced At-The-Market Under Nasdaq Rules